IBRX ImmunityBio (IBRX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001326110
Congress · 1Form 144 · 2
Insider buyers, 180 days
0
Funds added, last quarter
205
13F, latest reported quarter
Conversions, 180 days
9
Codes C/M, not in net · $1.1M priced
What the filings say about IBRX
Insiders, 180 days
-$5.0M net sold
3 sellers · 25% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-09-30
Planned sales (Form 144), 90 days
$8.4M
2 notices
ImmunityBio insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ImmunityBio, Inc. insiders sold a net $5.0M of stock across 29 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Jun 24, 2026.
- The trade is 0.9% of the 2,777,788 shares held after it.
- 1 other insider sold within 30 days.
- 205 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Simon Barry J. sold about $268.8K of IBRX under a 10b5-1 plan on Oct 5, 2026; 1 other insider sold within 30 days and 205 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Jul 2, 2026.
- The trade is 80.8% of the 100,309 shares held after it.
- 1 other insider sold within 30 days.
- 205 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Cohen Cheryl sold about $851.1K of IBRX under a 10b5-1 plan on Oct 2, 2026; 1 other insider sold within 30 days and 205 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 23, 2021.
- The trade is 104.6% of the 125,386 shares held after it.
- 2 other insiders sold within 30 days.
- 205 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Cohen Cheryl sold about $1.2M of IBRX on Jul 2, 2026; 2 other insiders sold within 30 days and 205 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Jun 30, 2026.
- 2 other insiders sold within 30 days.
- 205 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Selecky Christobel sold about $1.4M of IBRX on Jul 1, 2026; 2 other insiders sold within 30 days and 205 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jun 29, 2026.
- 2 other insiders sold within 30 days.
- 205 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Selecky Christobel sold about $9.0K of IBRX on Jun 30, 2026; 2 other insiders sold within 30 days and 205 funds added in the latest 13F quarter.29 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$5.0M over 180 days
-$1.1M over 90 days
below 79% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
205 funds bought in last quarter
more than 91% of Pharma & Biotech
Revenue
+668.3% year over year
more than 95% of Pharma & Biotech
Margin
-310.2% net margin
below 72% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
30.5% of the float short (float per yahoo 2026-10-26) · 8.9 days to cover · settled 2026-09-30
more than 77% of Pharma & Biotech
The situation: each line is one rule over one dataset
2 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Oct 12Rep. Lisa McClain sold $1.0K to $15K, disclosed 12 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.
Oct 6Director Cohen Cheryl sold $851.1K under a 10b5-1 plan (Oct 2)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 6Director Simon Barry J. sold $268.8K under a 10b5-1 plan (Oct 5)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 5Officer Simon Barry J. filed to sell $7.7M by Oct 5 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 2Director CHERYL COHEN filed to sell $752.2K by Oct 2 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch IBRX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+248.3%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns IBRX: institutional holders (13F)
13F holdings, latest reported quarter
34,083,262 sh
$298.4M
21,398,438 sh
$187.3M
17,863,911 sh
$156.4M
15,691,579 sh
$137.4M
11,551,019 sh
$101.1M
Congress trades in IBRX
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-09-30 · disclosed 12 days later
$1,001 - $15,000
Bought 2026-09-28 · disclosed 14 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
IBRX planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Simon Barry J.
Filed 2026-10-05
$7.7M
CHERYL COHEN
Filed 2026-10-02
$752.2K
CHERYL L COHEN
Filed 2026-07-02
$1.2M
CHRISTOBEL SELECKY
Filed 2026-07-01
$1.4M
CHRISTOBEL SELECKY
Filed 2026-06-30
$8.8K
IBRX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
WP Large Cap Income Plus Fund
$3.5M position · as of 2026-05-31
13.3%
Trenchless Fund ETF
$9.8M position · as of 2026-06-30
7.0%
VanEck Social Sentiment ETF
$3.8M position · as of 2026-06-30
3.7%
iShares Genomics Immunology and Healthcare ETF
$5.9M position · as of 2026-07-31
3.1%
Golden Eagle Dynamic Hypergrowth ETF
$1.7M position · as of 2026-06-30
2.4%
TFA AlphaGen Fund (formerly, the TFA AlphaGen Growth Fund)
$967.4K position · as of 2026-06-30
1.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
77 registered trials, 22 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
16
Phase 1
5 active
25
Phase 2
12 active
6
Phase 3
1 active
3
Not applicable
1 active
27
Multi-phase
3 active
What changed recently
NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill
2026-09-26 · Completion moved 2027-10-12 → 2028-05-12
Phase 2
A Study to Examine Anktiva for the Treatment of COVID-19.
2026-09-25 · Completion moved 2026-07 → 2027-03
Phase 2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Richard
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$12.7M
$6.2M
$5.8M
-85%
+20%
2024
$11.0M
$4.1M
$5.8M
-81%
-9%
2023
$1.2M
$262.4K
$961.7K
-62%
-8%
2022
$4.0M
$2.8M
$2.7M
-62%
-11%
2021
$29.0M
$10.4M
$2.9M
-54%
-1%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $5.0M sold by insiders over 180 days, 205 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $8.4M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
IBRX financials
Revenue growth
+668.3%
XBRL, annual
Net margin
-310.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$165.8M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM IBRX
| FY Dec 2025 | $113.3M |
| FY Dec 2024 | $14.7M |
| FY Dec 2023 | $622.0K |
| FY Dec 2022 | $240.0K |
| FY Dec 2021 | $934.0K |
| Jun 2026 | $51.2M |
| Mar 2026 | $44.2M |
| Dec 2025 | $38.3M |
| Sep 2025 | $32.1M |
| Jun 2025 | $26.4M |
| Mar 2025 | $16.5M |
| Dec 2024 | $7.6M |
| Sep 2024 | $6.1M |
At each fiscal year end
Single quarter
Net margin, TTM
-598.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM IBRX
| FY Dec 2025 | -310.3% |
| FY Dec 2024 | -2,805% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -449.6% |
| Mar 2026 | -1,431% |
| Dec 2025 | -162.1% |
| Sep 2025 | -209.8% |
| Jun 2025 | -350.3% |
| Mar 2025 | -784.9% |
| Dec 2024 | -783.9% |
| Sep 2024 | -1,404% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$288.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM IBRX
| FY Dec 2025 | -$308.8M |
| FY Dec 2024 | -$398.1M |
| FY Dec 2023 | -$397.3M |
| FY Dec 2022 | -$415.7M |
| FY Dec 2021 | -$308.0M |
| Jun 2026 | -$70.0M |
| Mar 2026 | -$77.1M |
| Dec 2025 | -$71.3M |
| Sep 2025 | -$69.6M |
| Jun 2025 | -$80.8M |
| Mar 2025 | -$87.0M |
| Dec 2024 | -$87.3M |
| Sep 2024 | -$101.6M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity IBRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-318.03x
TTM operating cash flow over current debt only, 2026-03-31
Cash flow to debt IBRX
| FY Dec 2025 | -174.15x |
| FY Dec 2024 | -313.49x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -318.03x |
| Mar 2026 | -333.02x |
| Dec 2025 | -174.15x |
| Sep 2025 | -122.82x |
| Jun 2025 | -280.09x |
| Mar 2025 | -296.60x |
| Dec 2024 | -313.49x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity IBRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-192.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets IBRX
| FY Dec 2025 | -79.5% |
| FY Dec 2024 | -93.2% |
| FY Dec 2023 | -134.7% |
| FY Dec 2022 | -100.4% |
| FY Dec 2021 | -101.3% |
| Jun 2026 | -192.6% |
| Mar 2026 | -179.8% |
| Dec 2025 | -79.5% |
| Sep 2025 | -78.9% |
| Jun 2025 | -86.8% |
| Mar 2025 | -116.2% |
| Dec 2024 | -93.2% |
| Sep 2024 | -147.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital IBRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-55.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed IBRX
| FY Dec 2025 | -66.7% |
| FY Dec 2024 | -88.9% |
| FY Dec 2023 | -235.5% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -260.9% |
| Jun 2026 | -55.8% |
| Mar 2026 | -62.7% |
| Dec 2025 | -66.7% |
| Sep 2025 | -68.1% |
| Jun 2025 | -77.8% |
| Mar 2025 | -104.2% |
| Dec 2024 | -88.9% |
| Sep 2024 | -111.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing IBRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$8.6B
market value at close 2026-10-23 on 2026-07-31 shares, plus current debt only, 2026-03-31, minus cash 2026-06-30
Enterprise value IBRX
| FY Dec 2025 | $1.9B |
| FY Dec 2024 | $1.6B |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $9.1B |
| Mar 2026 | $7.7B |
| Dec 2025 | $1.9B |
| Sep 2025 | $2.3B |
| Jun 2025 | $2.2B |
| Mar 2025 | $2.5B |
| Dec 2024 | $1.6B |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-3.3%
TTM free cash flow over market value at close 2026-10-23
FCF yield IBRX
| FY Dec 2025 | -15.8% |
| FY Dec 2024 | -22.3% |
| FY Dec 2023 | -11.9% |
| FY Dec 2022 | -20.5% |
| FY Dec 2021 | -12.7% |
| Jun 2026 | -3.1% |
| Mar 2026 | -3.8% |
| Dec 2025 | -15.8% |
| Sep 2025 | -14.0% |
| Jun 2025 | -15.3% |
| Mar 2025 | -14.7% |
| Dec 2024 | -22.3% |
| Sep 2024 | -16.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing IBRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $113.3M | $14.7M | $622.0K | $240.0K |
| Operating income | -$256.0M | -$344.2M | -$362.2M | -$351.3M |
| Net income | -$351.5M | -$413.6M | -$583.9M | -$417.3M |
| EPS (diluted) | -0.38 | -0.62 | -1.15 | -1.04 |
| Operating cash flow | -$304.9M | -$391.2M | -$366.8M | -$337.5M |
| Cash | $88.3M | $143.4M | $265.5M | $104.6M |
SEC XBRL, fiscal years, as known on 2026-10-27
IBRX Stock Sonar score 6/7 axes
Find similar shapesCompareIBRX ranks highest on growth (95th percentile) and institutional and government (58th), and lowest on financial health (4th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
IBRX filings, in plain words
Are ImmunityBio insiders buying or selling IBRX?
In the 180 days to 2026-10-27, ImmunityBio insiders were net sellers, a net $5.0M across purchases and sales reported on Form 4, by 3 sellers.
Have members of Congress traded IBRX?
Yes. In the year to 2026-10-27, 1 House member disclosed buying IBRX and 0 House members disclosed selling it; the latest on record is a purchase by Lisa McClain dated 2026-09-30.
Are there planned insider sales of IBRX?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $8.4M of stock; the latest, by Simon Barry J., was filed 2026-10-05.
Read the full summary
In the 180 days to 2026-10-27, ImmunityBio insiders were net sellers of IBRX, a net $5.0M across purchases and sales reported on Form 4 by 3 sellers. 25% of the 8 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-27, 1 member of Congress disclosed buying IBRX and 0 members disclosed selling it; the latest on record is a purchase by Lisa McClain dated 2026-09-30. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $8.4M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
